NASDAQ:OVID - Ovid Therapeutics Stock Price, Forecast & News

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 7.8% and is now trading at $2.89. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ovid Therapeutics.

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Ovid Therapeutics.

Ovid Therapeutics Inc (NASDAQ:OVID) released its quarterly earnings data on Wednesday, March, 11th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.06. View Ovid Therapeutics' earnings history.

6 brokerages have issued 12 month price targets for Ovid Therapeutics' shares. Their forecasts range from $10.00 to $20.00. On average, they anticipate Ovid Therapeutics' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 384.4% from the stock's current price. View analysts' price targets for Ovid Therapeutics.

News stories about OVID stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ovid Therapeutics earned a news impact score of 1.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutOvid Therapeutics.

Ovid Therapeutics saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,216,300 shares, an increase of 21.8% from the February 27th total of 1,820,000 shares. Based on an average daily volume of 629,400 shares, the days-to-cover ratio is presently 3.5 days. Approximately 9.8% of the shares of the company are sold short. View Ovid Therapeutics' Current Options Chain.

Some companies that are related to Ovid Therapeutics include Cara Therapeutics (CARA), ImmunoGen (IMGN), Retrophin (RTRX), Omeros (OMER), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), ZIOPHARM Oncology (ZIOP), Portola Pharmaceuticals (PTLA), Eagle Pharmaceuticals (EGRX), Vanda Pharmaceuticals (VNDA), ANI Pharmaceuticals (ANIP), Assembly Biosciences (ASMB), Vectura Group (VEGPF), Akero Therapeutics (AKRO) and INDIVIOR PLC/S (INVVY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Strongbridge Biopharma (SBBP), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), vTv Therapeutics (VTVT), Anavex Life Sciences (AVXL) and Genocea Biosciences (GNCA).

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (4.36%), Renaissance Technologies LLC (2.27%), AXA (1.81%), BVF Inc. IL (1.54%), Citigroup Inc. (1.05%) and Ikarian Capital LLC (0.73%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View institutional ownership trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, and Acadian Asset Management LLC. View insider buying and selling activity for Ovid Therapeutics.

OVID stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, AXA, Citigroup Inc., Renaissance Technologies LLC, Ikarian Capital LLC, Credit Suisse AG, Blair William & Co. IL, and Platinum Investment Management Ltd.. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein, and Pharmaceutical Co Ltd Takeda. View insider buying and selling activity for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $2.89.

Ovid Therapeutics has a market capitalization of $158.11 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe. View additional information about Ovid Therapeutics.

The official website for Ovid Therapeutics is http://www.ovidrx.com/.

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]